Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
115
resultados
Última actualización
11/05/2026 [07:10:00]
Resumen de: US20260124390A1
0000 An intelligent dosing platform incorporating comprehensive integration capabilities for non-syringe medication delivery devices including intelligent insulin pumps, intravenous delivery systems, and automated infusion devices. The platform features device integration modules configured to interface with pump-based delivery systems, dosage monitoring modules that track administration through continuous delivery mechanisms, and coordination modules managing treatment schedules across multiple device types. The system includes flow rate management capabilities for controlling infusion rates and pump delivery speeds, safety monitoring modules detecting occlusions and system malfunctions, and alert generation systems providing notifications for delivery interruptions and maintenance requirements. Data synchronization modules maintain consistent treatment records across pump systems and healthcare information networks, while remote monitoring capabilities enable healthcare provider oversight of device performance and patient response indicators. The platform incorporates compliance tracking, patient authentication, and predictive analytics modules for forecasting maintenance needs and optimizing multi-device treatment delivery coordination.
Resumen de: WO2026093759A1
The present invention relates to a microneedle electrode for detecting at least one analyte, such as glucose, ketones and/or lactate. The present invention also relates to a wearable device comprising one or more microneedle electrodes, as well as a process for detecting at least one analyte using the microneedle electrode and /or the wearable device of the present invention.
Resumen de: US20260127263A1
Systems, devices, and methods are provided for the control of interfacing between applications that facilitate the monitoring of diabetes running on a mobile device, including the authentication of a third party user interface application by a sensor interface application. Control of the display of current analyte levels and critical events is also provided.
Resumen de: US20260124114A1
A portable insulin cooler case includes a front cover and rear cover connected by a hinge forming an enclosure, and a closure mechanism positioned around perimeter edges providing secure sealing capabilities. The portable insulin cooler case includes a housing positioned on the front cover containing a display screen configured to display temperature information. The housing encompasses three buttons functioning as ON/OFF control, alarm control, and High/Low temperature recording control respectively. The portable insulin cooler case includes a first indented section formed within the front cover configured to receive a cooling device, and a thermometer positioned within the first indented section configured to monitor internal temperature. The first indented section includes elastic bands configured to secure insulin injection pens or insulin containers. The portable insulin cooler case includes a pocket formed between the front cover and rear cover configured to store diabetic accessories.
Resumen de: AU2024345572A1
Conditions of pathophysiologic dysglycemia, associated with type 1 diabetes, can be detected early, including in children. Glycemia data is collected by continuous glucose monitoring devices connected to a cloud server. The server learns person-specific patterns of glycemia and trains a model accordingly, which may serve as a baseline for comparison or as the basis for prediction of future patterns. Such models are conditioned by risk factors and various concurrent activities such as exercise and consumption of sugars. Person-specific models trained at different time periods give different simulated patterns of glycemia. Deviations between the simulated patterns, or between the predicted and actual patterns, can indicate progression of pathophysiologic dysglycemia and type 1 diabetes. These models and comparisons can be further interpreted by the software to result in a reported recommendation for additional diagnostic testing or a reported conclusion of diagnosis and recommendation of preventative intervention.
Resumen de: US20260127091A1
Disclosed are systems, methods, and articles for determining compatibility of a mobile application and operating system on a mobile device. In some aspects, a method includes receiving one or more data values from a mobile device having a mobile medical software application installed thereon, the data value(s) characterizing a version of the software application, a version of an operating system installed on the mobile device, and one or more attributes of the mobile device; determining whether the mobile medical software application is compatible with the operating system by at least comparing the received data value(s) to one or more test values in a configuration file; and sending a message to the mobile device based on the determining, the message causing the software application to operate in one or more of a normal mode, a safe mode, and a non-operational mode.
Resumen de: US20260123895A1
A method of predicting future blood glucose concentrations of an individual patient includes: selecting an individualized nonlinear physiological model of glucose-insulin dynamics, the selected model having a plurality of model parameters whose values are to be determined; estimating values for each of the model parameters in the plurality of model parameters, a first subset of the model parameters having values estimated from a priori population data and a second subset of the model parameters having values personalized for the individual patient by applying a parameter estimation technique to a priori information and data for the individual patient to obtain a posteriori information; and; applying a nonlinear prediction technique to the selected model using the estimated values for each of the model parameters to obtain a predicted blood glucose concentration of the individual patient at a future time.
Resumen de: EP4738376A2
The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include adjusting user specific dosage parameters in response to a user provided insulin delivery amount, including a user provided insulin delivery amount that varies from a recommended insulin delivery amount.
Resumen de: WO2026089758A1
Provided are a method, system, and computer-readable medium for recommending titration measurement for basal insulin dosing and then automatedly causing delivery of the dosing. The recommendation can be personalized to accomplish a weekly recommended dosing according to evaluation for a daily titration glucose level (TGL) determined for received CGM data over the course of a preceding weekly time period. With increased receipt of CGM data, the TGLs can be categorized according to refinement for risk of occurrence of hypoglycemia, and the recommendation may be provided commensurately. In any instance, the recommendation can be automatedly adjusted either upon the CGM data satisfying conditions for hypoglycemia or upon a patient self-reporting hypoglycemia.
Resumen de: US20260115379A1
0000 Disclosed herein are portable infusion pump systems that provide an ability to simultaneously track insulin on board from insulin deliveries from different sources and/or of different types. A user interface can be provided to enable the user to enter insulin delivered from a source other than the portable infusion pump. A simplified calculation for estimating IOB remaining from each insulin delivery enables such calculations to be carried out with the limited memory and processing capacity of the portable infusion pump.
Resumen de: US20260114743A1
A biometric wearable device is embodied in a finger ring or smart watch with radiowave or microwave energy emitters/transmitters and energy receivers to measure the level of a biometric parameter such as body oxygenation, hydration, or glucose level. The energy emitter/transmitter and the energy receiver can be parallel, nested, and/or comprise a two-dimensional array. The device can further comprise a split ring resonator located between the energy emitter/transmitter and the energy receiver.
Resumen de: US20260115383A1
0000 A wearable device or system for monitoring food consumption can include a head-worn device such as eyewear which is worn by a person and a plurality of brain activity sensors on the head-worn device, wherein data from the plurality of brain activity sensors is analyzed to detect when the person is eating. This device can be used alone or as part of a closed-loop glucose level management system.
Resumen de: US20260120863A1
Methods and apparatus, including computer program products, are provided for processing analyte data. In some example implementations, a method may include generating glucose sensor data indicative of a host's glucose concentration using a glucose sensor; calculating a glycemic variability index (GVI) value based on the glucose sensor data; and providing output to a user responsive to the calculated glycemic variability index value. The GVI may be a ratio of a length of a line representative of the sensor data and an ideal length of the line. Related systems, methods, and articles of manufacture are also disclosed.
Resumen de: AU2026202716A1
A method of providing an event notification in a glucose monitoring system, comprises: determining whether an event occurs; in response to the occurrence of the event, determining whether the event occurs during a signal loss; determining whether to output a notification corresponding to the event based on a preset priority between the event and the signal loss in the case where the event occurs during the signal loss; and outputting the notification corresponding to the event according to the determination of whether to output the notification. the notification. pr p r
Resumen de: US20260114742A1
A biometric wearable device is embodied in a smart watch or finger ring with radiowave or microwave energy emitters/transmitters and energy receivers to measure the level of a biometric parameter such as body oxygenation, hydration, or glucose level. The energy emitter/transmitter and the energy receiver can be parallel, nested, and/or comprise a two-dimensional array. The device can further comprise a split ring resonator located between the energy emitter/transmitter and the energy receiver.
Resumen de: US20260120843A1
0000 A wearable device or system for monitoring food consumption can include a wrist-worn or finger-worn device which is worn by a person, a motion sensor on the wrist-worn or finger-worn device, eyewear which is worn by the person, and a camera on the eyewear which is activated to record food images when analysis of data from the motion sensor detects that the person is eating. This device can be used alone or as part of a closed-loop glucose level management system.
Resumen de: WO2026088027A1
A system (100) for health diagnosis using breath of user and lifestyle assessment is disclosed The system includes a breath analyzer device (110) that includes a breath chamber (120) to receive exhaled breath and detect concentration level of acetone, hydrogen, ethanol, hydrogen, ammonia, carbon monoxide, hydrogen sulphide, 5 lung capacity, hydrogen, methane, ammonia and hydrogen sulphide. The plurality of sensors (130) captures a photoplethysmography signal. A receiving module (160) receives data and the photoplethysmography signal. A disorder score generation module (170) analyses the data to generate a diabetic score, liver disorder score, respiratory disorder score, digestive. A nutrient score module (180) calculates a 10 nutrient score. A lifestyle score module (190) calculates a lifestyle score. A display module (200) displays diabetic score, liver disorder score, respiratory disorder score, digestive disorder score, kidney disorder score, nutrition score, lifestyle score, and the plurality of health parameters via a user interface.
Resumen de: WO2026087221A1
A control device for managing insulin delivery in a closed-loop system. The control device comprises a computation module. The computation module is configured to receive a target basal rate indicative of a rate of a target insulin delivery rate of an insulin pump and compute a supplemental basal rate if the target basal rate is greater than a rate threshold. The supplemental basal rate is sensibly equal to a difference between the target basal rate and the rate threshold. The control device also comprises an insulin management module. The insulin management module is configured to determine a recommendation value of a control parameter of the insulin pump. The recommendation value is based on the supplemental basal rate multiplied by a time period. The control device comprises a communication module. The communication module is configured to send the recommendation value to the insulin pump.
Resumen de: WO2024263758A1
Systems and methods are provided for determining patterns, trends, anomalies, and/or abnormalities in data relating to operation of an insulin delivery pump and user outcomes relating to an insulin delivery pump and determining certain actions and/or operational adjustments to improve the user outcomes, such as blood glucose levels. For example, troubleshooting actions may be recommended upon determining a pattern, trend, abnormality, and/or anomaly in blood glucose levels that is undesirable. In another example, operation of the insulin delivery pump may be adjusted based habits and/or behaviors of the user. For example, insulin delivery timing may be adjusted based on exercise, activity and/or eating patterns. Based on the detected patterns, trends, anomalies, and/or abnormalities, a user device such as a mobile phone or smart device may present prompts for more information, alerts, status updates, and other information intended to improve the user experience.
Resumen de: WO2024263756A1
Systems and methods are provided for determining patterns, trends, anomalies, and/or abnormalities in data relating to operation of an insulin delivery pump and user outcomes relating to an insulin delivery pump and determining certain actions and/or operational adjustments to improve the user outcomes, such as blood glucose levels. For example, troubleshooting actions may be recommended upon determining a pattern, trend, abnormality, and/or anomaly in blood glucose levels that is undesirable. In another example, operation of the insulin delivery pump may be adjusted based habits and/or behaviors of the user. For example, insulin delivery timing may be adjusted based on exercise, activity and/or eating patterns. Based on the detected patterns, trends, anomalies, and/or abnormalities, a user device such as a mobile phone or smart device may present prompts for more information, alerts, status updates, and other information intended to improve the user experience.
Resumen de: EP4732829A1
0001 A GLP-1-Fc-FGF21 double-target fusion protein composition and the use thereof. The composition comprises a GLP-1-Fc-FGF21 fusion protein and a buffer solution. In the composition, by means of adding the buffer solution, the generation of visible particles can be effectively controlled, and the stability of the GLP-1-Fc-FGF21 fusion protein is improved, so that the shelf life of a product can be prolonged. The composition can be used for treating and/or preventing metabolic diseases, such as diabetes, hyperlipidemia, obesity and diseases related to fatty liver.
Resumen de: US20260108215A1
0000 The present invention relates to a method for predicting the prognosis of intravitreal injection treatment, comprising the steps of: receiving OCT images and clinical information of a plurality of diabetic macular edema patients; extracting one or more major lesion information from the OCT images; training a multi-modal deep learning model by inputting the OCT images, the clinical information, and the one or more major lesion features, and outputting the intravitreal injection treatment prognosis of the diabetic macular edema patients; and predicting the prognosis of intravitreal injection treatment by inputting the OCT images, the clinical information, and the major lesion features of a specific diabetic macular edema patient to the trained multi-modal deep learning model.
Resumen de: US20260108742A1
Devices and methods described herein may, among other uses, favorably cause the activation and/or deactivation of vascular baroreceptors in order to achieve a desired impact on a physiological condition, such as baroreflex-regulated conditions, hypertension, hypotension, nervous system disorders, metabolic disorders, cardiovascular disease, heart failure, cardiac arrhythmia, renal disease, respiratory disease, diabetes, and insulin resistance. The devices and methods may be used in concert with each other and/or other treatments, medications, interventions, or behavioral regimens. They may also be used in concert with devices and methods that perform or assist with assessing or measuring a mammal's blood pressure, assessing, measuring, or predicting the impact of the described methods and devices on the patient's condition (including blood pressure), and/or protecting the surrounding anatomy from adverse effects.
Resumen de: WO2026083250A1
The objective invention provides a parenteral composition of semaglutide or a pharmaceutically acceptable salt thereof for subcutaneous administration, having a strength and composition such that it can be administered multiple times from single article of manufacture, for use in treating type 2 diabetes mellitus and for weight loss, thereby providing benefit to the patient.
Nº publicación: AU2026202583A1 23/04/2026
Solicitante:
UNIVERSITY OF VIRGINIA PATENT FOUNDATION D/B/A UNIVERSITY OF VIRGINIA LICENSING AND VENTURES GROUP
Resumen de: AU2026202583A1
22573194_1 (GHMatters) P45417AU02 An insulin device configured to control an insulin dosage by adapting a basal rate profile. The insulin device includes a sensor configured to produce a blood glucose level measurement data, and detect changes of the blood glucose level measurement data over time; a processor and associated computer memory device configured to receive the blood glucose level measurement data and a basal rate profile, such that the basal rate profile includes a basal rate set point that corresponds to an insulin delivery reference for a nominal blood glucose, and the basal rate profile is stored in the computer memory device. The insulin device also includes an an insulin dispensing valve controlled by the processor to administer insulin in accordance with the received basal rate profile, such that the processor is configured to update the basal rate set point over a time period based on both an assessment of at least one of a risk of hyperglycemia and a risk of hypoglycemia from historical blood glucose data, and patterns of actions taken by the insulin device to mitigate glycemic risk during the time period. The insulin dispensing valve is controlled by the processor to administer insulin in accordance with the updated basal rate set point. pr p r
BOPI
Sede Electrónica
